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ABSTRACT During the past two decades, rectal cancer
treatment has improved considerably in Europe. Clinical
trials played a crucial role in improving surgical tech-
niques, (neo)adjuvant treatment schedules, imaging, and
pathology. However, there is still a wide variation in out-
come after rectal cancer. In most western health care
systems, efforts are made to reduce hospital variation by
focusing on selective referral and encouraging patients to
seek care in high-volume hospitals. On the other hand, the
expertise for diagnosis and treatment of common types of
cancer should be preferably widespread and easily acces-
sible for all patients. As an alternative to volume-based
referral, hospitals and surgeons can improve their results by
learning from their own outcome statistics and those from
colleagues treating a similar patient group. Several Euro-
pean surgical (colo)rectal audits have led to improvements
with a greater impact than any of the adjuvant therapies
currently under study. However, differences remain
between European countries, which cannot be easily
explained. To generate the best care for colorectal cancer in
the whole of Europe and to meet political and public
demands for transparency, the European CanCer Organi-
sation (ECCO) initiated an international, multidisciplinary,
outcome-based quality improvement program: European
Registration of Cancer Care (EURECCA). The goal is to
create a multidisciplinary European registration structure
for patient, tumor, and treatment characteristics linked to
outcome registration. Clinical trials will always play a
major role in improving rectal cancer treatment. To further
improve outcomes and diminish variation, EURECCA will
establish the basis for a strong, multidisciplinary, interna-
tional audit structure that can be used as a template for
similar projects worldwide.
During the past two decades, rectal cancer treatment has
improved considerably in Europe. Whereas this counts for
most solid malignancies, improvements in diagnosing and
treating rectal cancer surpass virtually all others. In the
early 1990s, outcome after rectal cancer treatment was
poor, with survival and recurrence rates of approximately
45%.
1 Nowadays, survival after rectal cancer is sometimes
even higher than after colon cancer.
2,3 Although radio-
therapy and chemotherapy are very important in modern
multidisciplinary treatment of rectal cancer, surgery
remains the inevitable cornerstone for cure. For all the
improvement in surgical techniques, (neo)adjuvant treat-
ment schedules, imaging and pathology, clinical trials, and
population-based audit registrations played a crucial role.
EARLY SWEDISH TRIALS
During the early 1970s in Sweden, local recurrence after
rectal cancer surgery was 38%, and the majority of those
patients never developed distant metastases.
4 Although it
was known that radiotherapy could reduce local recurrence,
a major question remained whether radiotherapy should be
given before or after the operation. Between 1980 and
1985, the ‘‘Uppsala trial’’ randomized 471 patients with
rectal cancer to preoperative 25 Gy radiotherapy or post-
operative 60 Gy radiotherapy. Postoperative radiotherapy
had an inferior tolerance compared with preoperative
radiotherapy. Besides, 46% of the patients could not start
postoperative radiotherapy within 6 weeks after surgery
because of complicated postoperative recovery. After a
mean follow-up of 6 years, local recurrence in the preop-
erative radiotherapy group was 12% compared with 21% in
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5
Simultaneously with the ‘‘Upssala trial,’’ the ‘‘Stock-
holm Rectal Cancer Study Group’’ started the ‘‘Stockholm
I’’ trial, which randomized 849 patients with rectal cancer
between preoperative 25 Gy radiotherapy versus surgery
alone. After a median follow-up of 9 years, local recur-
rence in the irradiated group was 14% compared with 28%
in the surgery alone group. Cancer-speciﬁc death was
lower in the irradiated group. However, postoperative
mortality within 30 days of surgery was increased after
radiotherapy, mainly in elderly patients, resulting in an
equal overall survival in both arms.
6
With the objective to reduce postoperative mortality
while maintaining the reduction of local recurrences, a new
study was initiated with a reduced irradiated volume and
exclusion of patients older than 80 years: the Stockholm II
trial.Between1987and1993,557patientswererandomized
between 25 Gy radiotherapy followed by surgery within a
week or surgery alone. After a median follow-up of 9 years,
localrecurrenceintheirradiatedgroupwas12%versus25%
in the surgery alone group. With the reduced irradiation
volume and the exclusion of older patients, there was no
signiﬁcant difference in postoperative mortality. Neverthe-
less, there was still no difference in overall survival.
7
Between 1987 and 1990, the Swedish Rectal Cancer
Trial randomized 1,168 patients younger than aged
80 years with resectable rectal cancer to undergo preop-
erative 25 Gy radiotherapy followed by surgery within
1 week or to have surgery alone. After 5 years, the local
recurrence ratio in the irradiated group was 11% compared
with 27% in the surgery alone group. In contrast to the
earlier trials, preoperative radiotherapy improved survival
in the Swedish Rectal Cancer Trial: the overall 5-year
survival rate was 58% in the irradiated group and 48% in
the surgery alone group (p = 0.004).
8
TOTAL MESORECTAL EXCISION ERA
In 1979, Heald stated that mesorectal tissue should be
removed together with the tumor to reduce local recur-
rence.
9 Together with Enker he popularized the total
mesorectal excision (TME) technique: a complete and
sharp excision of the mesorectum under direct vision, with
preservation of the hypogastric plexus.
10 During the late
1990s, both TME pioneers convinced the surgical world
with 5-year local recurrence rates \10% in patients with
rectal cancer who were operated on with the TME tech-
nique without (neo)adjuvant therapy.
Because all studies showing positive effects of radio-
therapy were performed with conventional surgery on top
of the fact that TME surgery alone came with low local
recurrence rates, the Dutch Colorectal Cancer Group con-
ducted a trial to study the effects of preoperative
radiotherapy in combination with TME surgery: The TME
Trial.
11 The new surgical technique was implemented in a
structured way. All participating surgeons were trained in
the TME technique by workshops and videotapes. At least
ﬁve procedures of each participating surgeon were super-
vised by an instructor surgeon. Pathologists were trained to
examine the specimens according to the protocol of Quirke
et al. regarding the circumferential resection margin
(CRM), lymph nodes, and dissection plane.
12
Between 1996 and 1999, 1,861 patients were random-
ized for the TME trial. Five-year local recurrence rate were
5.6% with and 10.9% without preoperative radiotherapy
and a 5-year overall survival of 64% in both groups.
13 Ten-
year follow-up data of the TME trial will be published in
the near future.
The transition from conventional surgery to a quality-
controlled multidisciplinary treatment regimen was not
limited to the trial population. In the Netherlands, survival
improved for all rectal cancer patients treated in the
Comprehensive Cancer Centres South and West. Before
the TME trial (1990–1995), 5-year overall survival after
rectal cancer was 56%, during the trial (1996–1999) it was
62%, and after the TME trial (2000–2002) 65%.
14 This
means that the traditional survival backlog of rectal cancer
compared with colon cancer has been completely nulliﬁed,
proving the lasting positive effects that standardization and
quality assurance in surgical oncology can have.
3
In some countries, chemoradiotherapy was preferred as
a standard therapy for rectal cancer instead of only radio-
therapy. The German Rectal Cancer Study Group
compared preoperative chemoradiotherapy with postoper-
ative chemoradiotherapy for patients with locally advanced
rectal cancer, operated with TME surgery. Between 1995
and 2002, 421 patients were included. Five-year local
recurrence was 6% in the group assigned to preoperative
chemoradiotherapy compared with 13% in the postopera-
tive chemoradiotherapy group. There also was reduced
toxicity in the preoperative chemoradiotherapy group but
no survival advantage.
15
The Polish Rectal Cancer Trial investigated whether
preoperative chemoradiation offered an advantage in
sphincter preservation compared with preoperative short-
term radiation for patients with resectable T3-T4 rectal
cancer operated with TME surgery. Between 1999 and
2002, 316 patients were included. Despite signiﬁcant
downsizing in the chemoradiation group, there was no
difference in sphincter preservation, local control, late
toxicity, or survival.
16,17
Because irradiating all patients with rectal cancer pos-
sibly overtreats certain patient groups, the MRC CR07/
NCIC-CTG C016 trial compared 25 Gy preoperative
692 W. van Gijn, C. J. H. van de Velderadiotherapy with selective postoperative chemoradiother-
apy restricted to patients with an involved circumferential
margin. After 3 years, local recurrence was 4.4% in the
group treated with preoperative radiotherapy compared
with 10.6% in the selective postoperative chemoradiother-
apy group. There was no difference in overall survival.
18
ADJUVANT CHEMOTHERAPY FOR RECTAL
CANCER
In contrast to colon cancer, there is not much evidence
that adjuvant chemotherapy improves survival for patients
with rectal cancer. The only study that showed an improved
survival after chemotherapy is the Japanese ‘‘National
Surgical Adjuvant Study of Colorectal Cancer.’’ Two hun-
dred seventy six patients with a completely resected stage
III rectal cancer were randomized between 1 year of uracil-
tegafur or no adjuvant treatment. Three-year overall sur-
vival was 91% in the uracil group compared with 81% in the
surgery-alone group (p = 0.005).
19 However, there are
many differences between the treatment given in this trial
and in Europe. Selective lateral pelvic lymphadenectomy is
only standardly performed in Japan in contrast to radio-
therapy, which is standard in Europe but not in Japan.
Furthermore, uracil is no longer the regimen of ﬁrst choice.
The EORTC 22921 trial evaluated preoperative and/or
postoperative ﬂuorouracil-based chemotherapy as an addi-
tiontopreoperativeradiotherapyforthetreatmentofpatients
with T3/T4 rectal cancer;1,011 patients were enrolled in the
trial. After a median follow-up of 5 years, chemotherapy
showed signiﬁcant beneﬁts on local recurrence rates. How-
ever, it had no effect on survival, regardless if it was given
preoperatively, postoperatively, or both.
20 Whereas patients
were enrolled between 1993 and 2003, TME surgery was
only recommended since the beginning of 1999.
To evaluate the effect of postoperative chemotherapy for
patients with stage II and III rectal cancer who are treated
with standardized TME surgery, the Dutch Colorectal
Cancer Group initiated the PROCTOR (Preoperative
Radiotherapy and / Or adjuvant Chemotherapy combined
with TME-surgery in Operable Rectal cancer) trial in 2000.
In 2004, the trial was succeeded by the SCRIPT (Simply
Capecitabine in Rectal Cancer after Irradiation Plus TME)
trial. While still open for accrual, an interim analysis of the
SCRIPT and PROCTOR trials will be published in the near
future.
QUALITY ASSURANCE AND SURGICAL AUDIT
REGISTRATIONS IN EUROPE
In Europe, 5-year relative survival for colorectal cancer
varies between 32% and 64%.
21 In most western health
care systems, efforts are made to reduce hospital variation
by focussing on selective referral and encouraging patients
to seek care in high-volume hospitals. Such a strategy of
treating a larger proportion of patients in specialized cen-
ters can evidently improve outcomes for complex surgical
procedures, such as esophagectomies and pancreatecto-
mies.
22 However, the expertise for diagnosis and treatment
of common types of cancer should be preferably wide-
spread and easily accessible for all patients. Besides, one
must keep in mind that there will always be low-volume
providers that perform very well just as there are high-
volume providers with unacceptable outcomes.
As an alternative to volume-based referral, hospitals and
surgeons can improve their results by learning from their
own outcome statistics and those from colleagues treating a
similar patient group. Surgical audit is a quality instrument
that collects detailed clinical data from different health care
providers, which can be adjusted for baseline risk and
subsequently fed back to individual hospitals or surgeons.
In this way, ‘‘best practices’’ can be identiﬁed, communi-
cated, and broadly adopted. After casemix adjustments, a
fair judgement can be made on the quality of cancer
treatments. Hospitals and surgeons can be faced with their
own results compared with those of colleagues treating the
same patient category. Another important advantage is the
fact that audit registries include the entire patient popula-
tion, which makes it possible to perform research on
patient groups that are usually excluded from clinical trials
(e.g., elderly, high comorbidity).
Between 1993 and 2009, eight surgical (colo)rectal
audits were set up in Europe. The Norwegian Rectal
Cancer Project included more than 99% of the Norwegian
patients with rectal cancer. After 4 years the proportion of
TME surgery increased from 78% to 92% and the local
recurrence rate decreased from 28% to 7%.
23 Moreover,
the audit showed to be very cost effective with every saved
life being less then €700.
24
In the Swedish Rectal Cancer Registry, postoperative
mortality decreased to\2.5% and the local recurrence rate
decreased to \10%. Survival improved dramatically:
patients with rectal cancer had an even better 5-year sur-
vival rate than those with colon cancer.
2
The Danish Colorectal Cancer Database also had satis-
fying results. Since 1994, 93% of all patients with
colorectal cancer were included. After 5 years of auditing,
5-year survival increased from 42% to 63% for women and
from 37% to 55% for men.
25
For the National Bowel Cancer Audit Programme
(NBOCAP), 95% of trusts in England and Wales submit
data. Within 5 years, 30-day mortality decreased from 7%
to 4.5%.
26
In 2000, the ‘‘International Quality Assurance in Colo-
rectal Carcinoma’’ was initiated in Magdeburg, Germany.
European Audit Improving Quality of Care 693Between 2000 and 2008, 372 hospitals from Germany and
Poland included 57,429 patients. The percentage of
abdominoperineal excisions was signiﬁcantly reduced from
26.1% in 2000 to 21.3% in 2008.
27
The Belgian Project on Cancer of the Rectum (PRO-
CARE) standardized and implemented national guidelines
and started a prospective registration in 2006. Besides
registering crude outcome data after rectal cancer treat-
ment, extensive efforts and resources are used to train
surgeons, pathologists, and radiologists in the latest stan-
dards of rectal cancer treatment.
28
The Spanish TME project audit registration includes
[3,000 patients so far. First reports show a 30-day mor-
tality of 3.1% and an anastomotic leakage rate of 8.2%.
29
The Dutch Surgical Colorectal Audit (DSCA) reached a
100% national coverage within a year with more than
11,000 patients included since 2009. In a recently pub-
lished ﬁrst annual report, important ﬁndings were
discovered, such as the high percentage urgent and acute
surgery, even for many patients who had already visited a
surgeon in an outpatient setting. Given the fact that for
rectal cancer, mortality after elective surgery is only 2.4%
compared with 9.5% after acute surgery, it seems obvious
that many lives can be saved when these ‘‘unnecessary
urgent’’ patients are reduced.
30
EURECCA: AN INTERNATIONAL,
MULTIDISCIPLINARY, OUTCOME-BASED
QUALITY IMPROVEMENT PROJECT
OF THE EUROPEAN CANCER ORGANISATION
Although all national audits contributed to improved
results, differences remain between European countries
that cannot be easily explained. Considering the results,
there are differences in mortality, complications, recur-
rence, and survival. Moreover, there are substantial
differences in (neo)adjuvant treatment regimens. Whereas
in Sweden and the Netherlands most patients with rectal
cancer receive preoperative radiotherapy, in Norway it is a
minority (4% between 1993 and 1997).
24 Nevertheless,
local recurrence rates in Norway equal the rates in Sweden
and the Netherlands.
23 To generate the best care for colo-
rectal cancer in the whole of Europe and to meet political
and public demands for transparency, a deep and broad
insight in treatment outcomes is needed. A European audit
registration can realize transparency, benchmarking, and
feedback across nation’s borders and can rapidly lead to
less variation and improved outcomes around the continent.
Urged by these arguments, the European CanCer Organi-
sation (ECCO) initiated an international, multidisciplinary,
outcome-based quality improvement program: European
Registration of Cancer Care (EURECCA). The goal is to
create a multidisciplinary European registration structure
for patient, tumor, and treatment characteristics linked to
outcome registration (morbidity, mortality, locoregional
control, and survival). The registration will be used for
benchmarking and internal feedback among participants
and enhance further improvements in quality and efﬁciency
of cancer care. All eight audit registries described in this
article have given their full commitment to participate in
the EURECCA framework. Key partners are the European
CanCer Organisation, the European Society of Surgical
Oncology, the European Society for Therapeutic Radiology
and Oncologists, the European Organisation of Research
and Treatment of Cancer, and the national audit structures.
The EURECCA project has a strong clinical research
component complemented by the provision of practical
tools for care providers all aiming at the optimization of the
delivery of surgery, radiotherapy, and chemotherapy in
colorectal cancer. Among the main scopes of research is
the deﬁnition of the ‘‘core quality treatment standards,’’
which, by way of recommendations, will be systematically
disseminated to optimize current treatment patterns and
offer patients the maximum quality treatment locally
available with strategies to limit undesirable effects.
CONCLUSIONS AND FUTURE
Clinical trials contributed with a great extend to the
treatment improvements for rectal cancer. They showed
that preoperative radiotherapy is more effective in reducing
local recurrence than postoperative radiotherapy, also in
combination with TME surgery. However, only one trial
for which conventional surgery was used showed a survival
improvement so far. Until now, there is little evidence for
adjuvant chemotherapy for rectal cancer treatment. Finally,
trials demonstrated that preoperative chemoradiotherapy is
favorable compared with postoperative and that preopera-
tive chemoradiotherapy has no advantage over short course
preoperative radiotherapy when no downsizing is needed.
If downsizing is needed, the standard treatment at present
is chemoradiotherapy; the Dutch TME trial showed that
short-course 25 Gy radiotherapy followed by surgery
within 1 week does not shrink the tumor.
31 A trial that
examines the possible downsizing effects of short-course
25 Gy radiotherapy in combination with delayed surgery is
the Swedish ‘‘Stockholm III’’ trial. Control groups are
patients treated with short-course radiotherapy followed by
surgery within 1 week and patients treated with chemora-
diotherapy followed by delayed surgery. Accrual started
in 1998 and according to a recently published interim
analysis, compliance was acceptable and severe acute
toxicity was low. Based on the interim analysis, it seems
that short-course radiotherapy with delayed surgery has a
694 W. van Gijn, C. J. H. van de Veldedownstaging effect as opposed to short-course radiotherapy
without delayed surgery.
32
A possible explanation for the better results of preop-
erative therapy opposed to postoperative therapy might be
the fact that due to various reasons compliance is much
lower for postoperative therapy. Utilizing the better com-
pliance of preoperative therapy, ﬁnal adjustments are made
on the protocol of a new trial: The Dutch Swedish Rectal
Cancer Trial. The goal of this trial will be to evaluate the
combination of short course radiation therapy combined
with preoperative chemotherapy in patients with rectal
cancer with a high risk of local or distant recurrence
compared with standard preoperative chemoradiotherapy
and adjuvant chemotherapy.
Despite the amelioration brought by clinical trials,
national audit registries in surgical oncology have led to
improvements with a greater impact than any of the adju-
vant therapies currently under study. Moreover, they offer
the possibility to perform research on patients that are
usually excluded from clinical trials such as elderly. EU-
RECCA will advance future treatment improvements and
spread these to every cancer patient in Europe. It provides
opportunities to treat all patients evidence-based while it
offers a unique insight in social-economical matters, such
as the consequences of commercialisation, treatment
availability, and screening initiatives. Approximately 110
million people will be represented by EURECCA, much
more than can possibly be covered by systematic reviews
that currently represent the highest level of evidence. In
contrast, usually less than a percent of all (rectal) cancer
patients participate in clinical trials. However, evidence
and recommendations produced by EURECCA or other
similar population-based projects will be scored much
lower on the level of evidence scale. Possibly, the way
levels of evidence are assigned should be reconsidered in
the future.
Concluding, clinical trials will always play a major role
in improving rectal cancer treatment. To further improve
outcomes and diminish variation, EURECCA will establish
the basis for a strong, multidisciplinary, international audit
structure that can be used as a template for similar projects
worldwide. Although it is not uncommon for American
surgical journals to slightly exaggerate the title of arti-
cles,
33 we are convinced that the EURECCA format can
truly conquer the world.
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